| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Cdc7-IN-5 targets Cdc7 kinase, a serine-threonine protein kinase that plays a critical role in the initiation of DNA replication. Cdc7 phosphorylates the MCM helicase complex, which is essential for the activation of DNA replication origins. By inhibiting Cdc7 activity, the compound disrupts DNA replication initiation, leading to cell cycle arrest and potentially cell death in proliferating cells.
|
|---|---|
| ln Vitro |
Cdc7-IN-5 demonstrates potent in vitro inhibition of Cdc7 kinase. The compound's activity is typically assessed in kinase assays using purified recombinant Cdc7 enzyme and peptide or protein substrates. IC50 values are determined from dose-response curves generated in these enzymatic assays.
|
| ln Vivo |
Cdc7-IN-5 has potential for in vivo efficacy in models of cancer, as Cdc7 is a promising target for anticancer therapy due to its essential role in DNA replication. By disrupting Cdc7 activity, the compound may inhibit tumor cell proliferation. Further in vivo studies are needed to evaluate its pharmacokinetic properties, antitumor efficacy, and safety profile.
|
| Enzyme Assay |
In vitro enzyme assays for Cdc7-IN-5 involve measuring its inhibition of Cdc7 kinase activity. The assay typically uses purified recombinant Cdc7 enzyme and measures the phosphorylation of peptide or protein substrates in the presence of the compound. IC50 values are determined from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for Cdc7-IN-5 involve treating cancer cell lines with varying concentrations of the compound and measuring cell proliferation using MTT or other assays. Inhibition of Cdc7 activity can be assessed by measuring MCM phosphorylation using Western blotting or by analyzing DNA replication using BrdU incorporation assays.
|
| Animal Protocol |
In vivo animal experiments for Cdc7-IN-5 would typically involve administering the compound to tumor-bearing mouse models. Efficacy is evaluated by measuring tumor growth inhibition, survival rates, and biomarker changes such as DNA replication markers and cell cycle progression.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Cdc7-IN-5 are limited. The compound has a molecular weight of 445.47 and a molecular formula of C25H23N3O5. It typically exists as a solid at room temperature. Its absorption, distribution, metabolism, and excretion properties have not been fully characterized. Information concerning product stability, particularly in solution, has rarely been reported.
|
| Toxicity/Toxicokinetics |
Toxicological data for Cdc7-IN-5 are limited. As a research compound, comprehensive toxicological studies have not been reported. The compound is intended for research use only and is not for human therapeutic application. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Cdc7-IN-5 (CAS#: 1402057-86-6) has the molecular formula C25H23N3O5 and a molecular weight of 445.47. It is a potent inhibitor of Cdc7 kinase, which is essential for the initiation of DNA replication in the cell cycle. The compound has potential applications in cancer research. It is for research use only.
|
| Molecular Formula |
C25H23N3O5
|
|---|---|
| Molecular Weight |
445.467226266861
|
| Exact Mass |
445.163
|
| CAS # |
1402057-86-6
|
| PubChem CID |
136367815
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
33
|
| Complexity |
773
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOC(=O)C1=C(OC(=C1O)/C=C/2\C=NC3=C2C=CC=N3)N4CCC5=C(C4)C=C(C=C5)OC
|
| InChi Key |
JSRLUFXDTSIAKH-FOWTUZBSSA-N
|
| InChi Code |
InChI=1S/C25H23N3O5/c1-3-32-25(30)21-22(29)20(12-16-13-27-23-19(16)5-4-9-26-23)33-24(21)28-10-8-15-6-7-18(31-2)11-17(15)14-28/h4-7,9,11-13,29H,3,8,10,14H2,1-2H3/b16-12+
|
| Chemical Name |
ethyl 4-hydroxy-2-(7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)-5-[(Z)-pyrrolo[2,3-b]pyridin-3-ylidenemethyl]furan-3-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 12.5 mg/mL (28.06 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2448 mL | 11.2241 mL | 22.4482 mL | |
| 5 mM | 0.4490 mL | 2.2448 mL | 4.4896 mL | |
| 10 mM | 0.2245 mL | 1.1224 mL | 2.2448 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
